[go: up one dir, main page]

MA32894B1 - Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide - Google Patents

Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide

Info

Publication number
MA32894B1
MA32894B1 MA33935A MA33935A MA32894B1 MA 32894 B1 MA32894 B1 MA 32894B1 MA 33935 A MA33935 A MA 33935A MA 33935 A MA33935 A MA 33935A MA 32894 B1 MA32894 B1 MA 32894B1
Authority
MA
Morocco
Prior art keywords
cyclophosphamide
antibodies
specifically recognizing
combinations containing
containing specifically
Prior art date
Application number
MA33935A
Other languages
Arabic (ar)
English (en)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA32894B1 publication Critical patent/MA32894B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant un anticorps reconnaissant spécifiquement CD38 et du cyclophosphamide.
MA33935A 2008-11-28 2011-06-13 Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide MA32894B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08291119A EP2191843A1 (fr) 2008-11-28 2008-11-28 Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cyclophosphamide
PCT/IB2009/055392 WO2010061360A1 (fr) 2008-11-28 2009-11-27 Associations antitumorales contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide

Publications (1)

Publication Number Publication Date
MA32894B1 true MA32894B1 (fr) 2011-12-01

Family

ID=40637068

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33935A MA32894B1 (fr) 2008-11-28 2011-06-13 Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide

Country Status (29)

Country Link
US (2) US20110305690A1 (fr)
EP (2) EP2191843A1 (fr)
JP (3) JP2012510464A (fr)
KR (1) KR101749770B1 (fr)
CN (1) CN102264387B (fr)
AR (1) AR074221A1 (fr)
AU (1) AU2009321252B2 (fr)
BR (1) BRPI0922305B1 (fr)
CA (1) CA2745012C (fr)
CL (1) CL2011001256A1 (fr)
CO (1) CO6361947A2 (fr)
CR (1) CR20110283A (fr)
EA (2) EA026008B1 (fr)
EC (1) ECSP11011077A (fr)
HN (1) HN2011001426A (fr)
MA (1) MA32894B1 (fr)
ME (1) ME01139B (fr)
MX (1) MX340062B (fr)
MY (1) MY166530A (fr)
NI (1) NI201100104A (fr)
NZ (1) NZ593147A (fr)
PA (1) PA8850201A1 (fr)
PE (1) PE20110822A1 (fr)
SV (1) SV2011003925A (fr)
TW (1) TWI457346B (fr)
UA (1) UA104161C2 (fr)
UY (1) UY32267A (fr)
WO (1) WO2010061360A1 (fr)
ZA (1) ZA201103920B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191840A1 (fr) 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan
SG188345A1 (en) 2010-09-27 2013-04-30 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PL2900232T3 (pl) * 2012-09-25 2018-05-30 Morphosys Ag Kombinacje i ich zastosowania
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
JP2016536314A (ja) 2013-10-31 2016-11-24 サノフイ ヒトのがんを治療するための特異的抗ｃｄ３８抗体
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2016022589A2 (fr) 2014-08-08 2016-02-11 The Regents Of The University Of California Méthodes de traitement du myélome multiple
UA122212C2 (uk) 2014-09-09 2020-10-12 Янссен Байотек, Інк. Вид комбінованої терапії з застосуванням антитіла до cd38
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
MY198983A (en) 2015-05-20 2023-10-06 Janssen Biotech Inc Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
WO2016209921A1 (fr) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SG11201803678SA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2018002181A1 (fr) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. Traitement de maladies médiées par l'ige avec des anticorps qui se lient spécifiquement à cd38
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
CA3088199A1 (fr) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Dosage sous-cutane d'anticorps anti-cd38
TW202102541A (zh) 2019-03-15 2021-01-16 德商莫菲西斯公司 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
JP7670713B2 (ja) 2019-12-05 2025-04-30 サノフィ－アベンティス・ユー・エス・エルエルシー 皮下投与のための抗ｃｄ３８抗体の製剤
US20240109977A1 (en) 2021-01-14 2024-04-04 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
KR100663319B1 (ko) 1997-04-14 2007-01-02 마이크로메트 에이지 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2329940A1 (fr) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Traitement du myelome multiple au moyen d'anticorps du cd38 obtenus par genie genetique
GB0221574D0 (en) * 2002-09-17 2002-10-23 Isis Innovation Treatments
WO2006099875A1 (fr) * 2005-03-23 2006-09-28 Genmab A/S Anticorps diriges contre cd38 pour le traitement du myelome multiple
EP1914242A1 (fr) * 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
CA2712989C (fr) * 2008-01-23 2015-10-27 Xencor, Inc. Anticorps diriges contre cd40 optimises et leurs procedes d'utilisation
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб

Also Published As

Publication number Publication date
MY166530A (en) 2018-07-10
PA8850201A1 (es) 2010-07-27
CN102264387A (zh) 2011-11-30
ZA201103920B (en) 2012-09-26
TWI457346B (zh) 2014-10-21
JP6018235B2 (ja) 2016-11-02
PE20110822A1 (es) 2011-11-22
EA201100869A1 (ru) 2011-10-31
ECSP11011077A (es) 2011-07-29
HN2011001426A (es) 2014-01-13
AU2009321252B2 (en) 2016-06-09
MX340062B (es) 2016-06-23
NI201100104A (es) 2011-09-26
JP2017036297A (ja) 2017-02-16
CN102264387B (zh) 2015-04-08
CA2745012C (fr) 2020-09-15
EP2370097B1 (fr) 2019-01-09
KR20110096552A (ko) 2011-08-30
CA2745012A1 (fr) 2010-06-03
JP2012510464A (ja) 2012-05-10
JP6215429B2 (ja) 2017-10-18
HK1164154A1 (en) 2012-09-21
EA032934B1 (ru) 2019-08-30
CO6361947A2 (es) 2012-01-20
CR20110283A (es) 2011-09-20
BRPI0922305B1 (pt) 2022-04-05
EP2370097A1 (fr) 2011-10-05
TW201024315A (en) 2010-07-01
NZ593147A (en) 2012-12-21
EA026008B1 (ru) 2017-02-28
JP2015120729A (ja) 2015-07-02
AU2009321252A1 (en) 2010-06-03
UY32267A (es) 2010-06-30
ME01139B (me) 2013-03-20
CL2011001256A1 (es) 2012-01-27
AR074221A1 (es) 2010-12-29
KR101749770B1 (ko) 2017-06-22
EP2191843A1 (fr) 2010-06-02
US20170056496A1 (en) 2017-03-02
EA201692041A1 (ru) 2017-05-31
US20110305690A1 (en) 2011-12-15
UA104161C2 (uk) 2014-01-10
MX2011005538A (es) 2011-10-10
SV2011003925A (es) 2011-10-07
BRPI0922305A2 (pt) 2016-06-21
WO2010061360A1 (fr) 2010-06-03

Similar Documents

Publication Publication Date Title
MA32894B1 (fr) Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et du cyclophosphamide
MA32895B1 (fr) Combinaisons anticancéreuses contenant des anticorps reconnaissant spécifiquement cd38 et de la vincristine
MA32896B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et du melphalan
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
MA34816B1 (fr) Combinaisons antitumorales contenant des anticorps reconnaissant specifiquement le cd38 et du bortezomib
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
EP2484697A4 (fr) Anticorps antipodoplanine et composition pharmaceutique contenant un anticorps antipodoplanine
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
FR2963561B1 (fr) Composition pharmaceutique contenant un extrait de serenoa repens
MA55298A (fr) Compositions pharmaceutiques contenant des anticorps anti-lingo-1
TN2011000153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide